Feasibility of Oral Topotecan Plus Intravenous Paclitaxel in Advanced Non-Small-Cell Lung Cancer

Publisher： Karger

E-ISSN： 1423-0232|61|1|30-34

ISSN： 0030-2414

Source： Oncology, Vol.61, Iss.1, 2001-09, pp. : 30-34

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Preliminary Results of Combined Therapy with Topotecan and Carboplatin in Advanced Non-Small-Cell Lung Cancer

By  

Oncology, Vol. 61, Iss. 1, 2001-09 ,pp. : 47-54

Karger

Access to resources Recommend Favorite

Paclitaxel, Carboplatin, and G-CSF in Advanced Non-Small-Cell Lung Cancer: A Phase I/II Study

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1998-09 ,pp. : 310-314

Karger

Access to resources Recommend Favorite

Predicting Chemotherapy Response to Paclitaxel-Based Therapy in Advanced Non-Small-Cell Lung Cancer with P-Glycoprotein Expression

By  

Respiration, Vol. 70, Iss. 1, 2003-02 ,pp. : 32-35

Karger

Access to resources Recommend Favorite

Phase II Trial of Weekly Paclitaxel in Previously Untreated Advanced Non-Small-Cell Lung Cancer

By  

Oncology, Vol. 65, Iss. 3, 2003-12 ,pp. : 224-228

Karger

Access to resources Recommend Favorite

Feasibility of Oral Topotecan in Previously Untreated Patients with Small-Cell Lung Cancer Ineligible for Standard Therapy

By  

Oncology, Vol. 61, Iss. 1, 2001-09 ,pp. : 42-46

Karger

Access to resources Recommend Favorite